Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Serikawa, Takeshi
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
JNIR, NCT02828917: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial	Completed	N/A	104	Japan	MedJ-01 Ridaforolimus Eluting Coronary Stent System	Medinol Ltd.	de Novo or Restenosis Lesions	06/18	08/22
Matsukawa, Ryuichi
EMPA-AHF, NCT05392764: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	Recruiting	3	524	Japan	Empagliflozin 10 MG, Placebo	Juntendo University, Boehringer Ingelheim	Acute Heart Failure	03/25	12/27
Nozoe, Masatsugu
No trials found